A botanical drug composed of three herbal materials attenuates the sensorimotor gating deficit and cognitive impairment induced by MK‐801 in mice

Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice

(2016) Hee Kyong Oh et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Olanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1

(2016) Qingsheng Zhang et al.   Scientific Reports

Drug development in schizophrenia

(2015) Donald C. Goff   CURRENT OPINION IN PSYCHIATRY

Glutamate and dopamine in schizophrenia: An update for the 21st century

(2015) Oliver Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Toll-like receptor-2 deficiency induces schizophrenia-like behaviors in mice

(2015) Se Jin Park et al.   Scientific Reports

The role of inflammation in schizophrenia

(2015) Norbert Müller et al.   Frontiers in Neuroscience

Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia

(2014) Yoshiaki Miyamoto et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

A Dopamine D2 Receptor-DISC1 Protein Complex may Contribute to Antipsychotic-Like Effects

(2014) Ping Su et al.   NEURON

Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt

(2014) Cullen L Schmid et al.   NEUROPSYCHOPHARMACOLOGY

Anhedonia, avolition, and anticipatory deficits: Assessments in animals with relevance to the negative symptoms of schizophrenia

(2013) Samuel A. Barnes et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A serotonin hypothesis of schizophrenia

(2013) Arnold E. Eggers   MEDICAL HYPOTHESES

Prunella vulgarisAttenuates Prepulse Inhibition Deficit and Attention Disruption induced by MK-801 in Mice

(2013) Se Jin Park et al.   PHYTOTHERAPY RESEARCH

Glutamatergic Dysbalance and Oxidative Stress in In Vivo and In Vitro Models of Psychosis Based on Chronic NMDA Receptor Antagonism

(2013) Just Genius et al.   PLoS One

Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments

(2012) Maria D. Rubio et al.   Biomolecules & Therapeutics

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

(2012) S Miyamoto et al.   MOLECULAR PSYCHIATRY

Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia

(2012) George Anderson et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

AKT/GSK3 signaling pathway and schizophrenia

(2012) Effat S. Emamian   Frontiers in Molecular Neuroscience

Animal models of schizophrenia

(2011) CA Jones et al.   BRITISH JOURNAL OF PHARMACOLOGY

Group II Metabotropic Glutamate Receptor Agonist Ameliorates MK801-Induced Dysfunction of NMDA Receptors via the Akt/GSK-3β Pathway in Adult Rat Prefrontal Cortex

(2011) Dong Xi et al.   NEUROPSYCHOPHARMACOLOGY

From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

(2011) Bita Moghaddam et al.   NEUROPSYCHOPHARMACOLOGY

Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders

(2010) Wijnand Laan et al.   JOURNAL OF CLINICAL PSYCHIATRY

Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

(2010) Norbert Müller et al.   SCHIZOPHRENIA RESEARCH

Schizophrenia

(2009) Jim van Os et al.   LANCET

What We Know: Findings That Every Theory of Schizophrenia Should Explain

(2009) A. W. MacDonald et al.   SCHIZOPHRENIA BULLETIN

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Models of schizophrenia in humans and animals based on inhibition of NMDA receptors

(2008) Věra Bubeníková-Valešová et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS